Abstract 12173: Differences in Ascending Aortic Size in Bicuspid Aortic Valve Patients Treated with and without a Statin: A New Paradigm?
Objective: Ascending aortic dilatation (AAD) commonly occurs in patients with bicuspid aortic valve (BAV). Statins have been shown to reduce the expression of matrix metalloproteinases and slow the progression of abdominal aortic aneurysms. The role of statins in slowing AAD in patients with BAV is unknown. We sought to compare ascending aortic dimensions in patients with BAV treated with and without a statin.
Methods: From our catheterization laboratory database, all patients undergoing preoperative coronary angiography prior to aortic valve +/- ascending aorta replacement for BAV disease between 2004 and 2007 were identified. Ascending aortic size was measured on their preoperative transesophageal echocardiography. Data on statin use was obtained from chart review and ascending aortic size was compared in patients on and those not on a statin.
Results: The study sample included 147 patients of which 76 were treated with statins (mean age 62±9, 72% male) and 71 were not (mean age 59±12, 68% male). Total and LDL cholesterol and triglyceride levels were significantly lower in the statin group. Ascending aorta size was significantly lower in statin group (3.6 ± 0.7 cm vs. 3.9 ± 0.6 cm, p<0.01). Significantly fewer patients on a statin had ascending aorta ≥ 4 cm (34% vs. 54%, p<0.02). On multivariate analysis, statin use was the only independent predictor of aortic size and was associated with a 0.33 cm reduction in aortic size (95% CI 0.06-0.59, p<0.01).
Conclusion: Statin treated BAV patients have smaller ascending aortic size compared to statin untreated BAV patients. Studies evaluating role of statins in slowing progression of ascending aortic dilatation are warranted.
- © 2011 by American Heart Association, Inc.